Mustang Bio nasdaq Mbio Reports Promising Phase 12 Trial Results for Mb 106 Stock Jumps

Mustang Bio (NASDAQ: MBIO) Reports Promising Phase 1/2 Trial Results for MB-106, Stock Jumps

Mustang Bio (NASDAQ: MBIO) stock surged during intraday trading Wednesday after the company reported positive safety and efficacy data from its Phase 1/2 trial of MB-106.

Mustang Bio has shared encouraging updates from its Phase 1/2 clinical trial of MB-106, an autologous CAR T-cell therapy targeting CD20, in patients with Waldenstrom macroglobulinemia, a rare form of blood cancer.

Fred Hutch Cancer Center and Mustang Bio are developing MB-106 in collaboration to treat patients with relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia.

Brian Till, M.D., Associate Professor and physician at Fred Hutch and the University of Washington, presented the updated results from the single-institution Phase 1/2 clinical trial during a poster session at the European Hematology Association 2024 Hybrid Congress. He highlighted MB-106’s favorable safety and efficacy profiles.

Encouraging Results from Phase 1/2 Clinical Trial

The study involved ten patients, each of whom had previously been treated with Bruton’s tyrosine kinase inhibitors (BTKi) but had continued disease progression while on BTKi. The treatment with MB-106 demonstrated a remarkable 90% response rate (9 out of 10 patients), including:

  • Three complete responses
  • Two very good partial responses
  • Four partial responses
  • One patient achieved stable disease

Notably, one patient who achieved a complete response has remained in remission for 31 months, with normalized immunoglobulin M (IgM) levels persisting post-treatment.

Patients in the study had a median of nine prior lines of therapy. Post MB-106 treatment, only one patient required additional treatment for Waldenstrom macroglobulinemia.

From a safety perspective, the trial reported manageable cytokine release syndrome (CRS), with nine patients experiencing low-grade CRS (grade 1 or 2), and one patient encountering grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS). Even with dose escalation, the researchers did not observe any cases of grade 3 or 4 CRS or grade 2, 3, or 4 ICANS.

Fred Hutch scientists played a crucial role in these developments and may benefit financially from this research and its outcomes. However, Mustang Bio emphasizes the need for substantial funding or strategic partnerships to advance the MB-106 program for hematologic malignancies.

Mustang Bio (NASDAQ: MBIO) Stock Price Action

On Wednesday, MBIO stock jumped 13.35%, closing at $0.8501, marking a 471.30% increase for the week. The trading volume was 291,949,248 shares, significantly higher than the average daily volume of 25.43 million.